

Fig. 1





Fig. 2

SUBSTITUTE SHEET (RULE 26)

WO 2005/049607 PCT/9

2/7







Fig. 5





-1g. 4

WO 2005/049607 PCT/CA2004/002003




Fig. 6





Fig. 7

WO 2005/049607 PCT/CA2004/002003

0.60
0.50
0.40
0.30
0.20
0.10
0.00

Control co



*MTX is significantly different from control for the rest of the protocol.

Fig. 9

^{**} Compound 1 is significantly different from the control.

6/7





Fig. 10



Inflammation significantly inferior to control

Compound 19a IV: Days 1, 2, 3, 4, 5, 6, 12, 13, 14, 15, 16, 18 and 19

MTX: Days 5, 15, 16, 17, 18, 19 and 21 Compound 19a PO: Days 1, 3, 5 and 6 Compound 1 PO: Days 4, 5 and 16 Compound 1 IV: Days 16 and 19 —— Control —— MTX


—▲— Compound 1-IV

—■— Compound 19a-IV

— Compound 1-PO— Compound 19a-PO

Fig. 11

7/7



Inflammation significantly inferior to control

Compound 19a IV: Days 13, 14, 15, 16, 18 and 20.

Methotrexate: Days 14, 15, 16, 18 and 20. Compound 19a Par. Days 13, 14, 15, 16, 19, 20, 21 and 22.

-Control '

Methotrexate

-Compound 19a-IV

Compound 19a-PO

Fig. 12




Fig. 13